Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

The factor VIII component acts as a cofactor in the intrinsic coagulation cascade, enhancing the conversion of factor X to Xa, while von Willebrand factor stabilizes factor VIII in circulation and promotes platelet adhesion to damaged blood vessels. Together they restore normal clot formation.

The dose of Immunate is individualized. A qualified prescriber determines the amount and infusion rate based on the patient’s weight, severity of deficiency, and clinical situation. Dosing regimens are not standardized and must be set by a healthcare professional.

Safety data for Immunate in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant. Clinicians should evaluate each case carefully and discuss potential risks with the patient.

To order Immunate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Immunate combines both factor VIII and von Willebrand factor in a single preparation, which can simplify therapy for patients who need both proteins. Some alternatives provide only factor VIII or only von Willebrand factor, requiring separate products. The choice depends on the specific deficiency, patient profile, and clinician preference.

Immunate must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly according to the manufacturer’s guidance.

Immunate is given by intravenous infusion under medical supervision. The infusion rate and volume are determined by the prescribing clinician based on the patient’s weight and clinical needs. Administration should follow aseptic technique and be monitored for any infusion‑related reactions.

Serious risks include the development of inhibitory antibodies that neutralize factor activity, severe allergic reactions such as anaphylaxis, and thrombotic events like deep‑vein thrombosis. Patients should be monitored closely for signs of these reactions during and after infusion.

Immunate is contraindicated in patients with known hypersensitivity to any of its components, including human plasma‑derived proteins. It should also be avoided in individuals with a history of severe inhibitor formation unless under specialist guidance. Clinical judgment is required for patients with uncontrolled thrombotic disorders.